JHVEPhoto
- The U.S. FDA has approved Merck's (NYSE:MRK) Keytruda (pembrolizumab) as a treatment for head and neck squamous cell carcinoma whose tumors express PD-L1 in certain situations.
- The therapy is now approved as a single agent as neoadjuvant treatment, continued as adjuvant